Breaking News

BREAKING: Novartis Retreats, But Not Entirely, on 340B Contract Pharmacy (Update 2)

Novartis Retreats, But Not Entirely, on 340B Contract Pharmacy (Update 2)

Update 2, Friday Oct. 30, 4:00 p.m. EDT—Hospital group 340B Health said Novartis’ action was inexcusable. “The 340B statute is crystal clear,” 340B Health President and CEO Maureen Testoni said. Drug companies cannot “put limits on [340B] discounts based on where hospitals are distributing the drugs to their patients. Manufacturers that knowingly and intentionally overcharge for their drugs are subject to civil monetary penalties. It is long past time for the Department of Health & Human Services to put a stop to this unlawful behavior.”

.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer